Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide

Table 3

Outcomes of multivariate analyses.

Characteristic	Patients N (%)	Median OS (months)	HR (95% CI)	value
KPS
90–100	93 (60.8)	20.7	1.83 (1.69–1.97)	0.008
70–80	60 (39.2)	11.4
RTOG RPA class
III-IV	123 (80.4)	19.9	2.24 (2.06–2.42)	<0.001
V	30 (19.6)	8.3
Extent of surgery
Gross total	54 (35.3)	19.5	1.49 (1.38–1.60)	0.037
Subtotal/biopsy	99 (64.7)	12.4
CRP/Alb ratio
<0.75	104 (68.0)	22.5	2.41 (2.23–2.59)	<0.001
≥0.75	49 (32.0)	15.7

HR, hazard ratio; CI, confidence interval; KPS, Karnofsky performance score; RTOG RPA, radiation therapy oncology group recursive partitioning analysis; CRP/Alb, CRP to albumin ratio.